GU 16-257: Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle- invasive bladder cancer with selective bladder sparing: CIMACC-CIDC (Cohort 1)

ABSTRACT: GU 16-257: Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle- invasive bladder cancer with selective bladder sparing: CIMACC-CIDC (Cohort 1)

PROVIDER: PRJNA1001525 | ENA |

REPOSITORIES: ENA